Palvella Therapeutics (NASDAQ:PVLA) Coverage Initiated by Analysts at TD Cowen

TD Cowen initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note released on Wednesday, Marketbeat reports. The brokerage issued a buy rating and a $44.00 target price on the stock.

A number of other research firms also recently weighed in on PVLA. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of Palvella Therapeutics in a research note on Friday, January 10th. Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $14.76 on Wednesday. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $22.32. The company has a market capitalization of $165.61 million, a price-to-earnings ratio of -1.22 and a beta of 0.68.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins purchased 4,000 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was acquired at an average price of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the transaction, the director now directly owns 180,671 shares in the company, valued at $2,336,076.03. This represents a 2.26 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 6.39% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.